Teva’s Asthma Treatment Approved By FDA

March 27, 2016 | The US Food and Drug Administration (FDA) has approved Israel’s Teva Pharmaceutical Industries Ltd. CINQAIR injection for treating asthma. The drug treats asthma in adults who have a history of severe attacks despite taking medication. In the studies on which FDA approval was based, treatment with CINQAIR was associated with reduction in asthma exacerbations of up to 59 percent as well as significant improvement in lung function, symptoms, and asthma-related quality of life. This is the first approval of CINQAIR (reslizumab) anywhere in the world. The treatment is expected to become commercially available to patients, by prescription, during the second quarter of 2016. Teva was founded in 1901 and is currently headed by CEO Erez Vigodman.